Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
Audio webcast/conference call:
Additional international dial-in numbers are available here.
Conference ID: 8217388
Interested parties may register for the zanidatamab R&D Day webcast via the Investors section of the
A replay of the webcast will be available via the Investors section of the
About
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in
Contacts:
Jazz Investor Contact:
Vice President, Head, Investor Relations
InvestorInfo@jazzpharma.com
Jazz Media Contact:
Head of
CorporateAffairsMediaInfo@jazzpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-host-virtual-zanidatamab-rd-day-on-tuesday-march-19-2024-302087115.html
SOURCE